Seven Grand Managers LLC Purchases New Shares in Viridian Therapeutics, Inc. $VRDN

Seven Grand Managers LLC purchased a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $3,112,000. Seven Grand Managers LLC owned approximately 0.10% of Viridian Therapeutics at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Viridian Therapeutics by 12.8% during the 4th quarter. Geode Capital Management LLC now owns 1,992,174 shares of the company’s stock worth $62,007,000 after buying an additional 225,987 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Viridian Therapeutics by 48.2% during the 4th quarter. Fisher Asset Management LLC now owns 1,780,284 shares of the company’s stock worth $55,402,000 after buying an additional 579,058 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in Viridian Therapeutics by 107.1% during the 4th quarter. Simplify Asset Management Inc. now owns 103,531 shares of the company’s stock worth $3,222,000 after buying an additional 53,531 shares in the last quarter. Legato Capital Management LLC lifted its holdings in Viridian Therapeutics by 132.9% during the 4th quarter. Legato Capital Management LLC now owns 22,814 shares of the company’s stock worth $710,000 after buying an additional 13,018 shares in the last quarter. Finally, PSP Research LLC acquired a new position in Viridian Therapeutics during the 4th quarter worth $528,000.

Viridian Therapeutics Stock Performance

VRDN stock opened at $17.26 on Thursday. The business’s fifty day moving average is $18.17 and its 200-day moving average is $26.31. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.78 billion, a P/E ratio of -5.20 and a beta of 0.82. Viridian Therapeutics, Inc. has a twelve month low of $13.18 and a twelve month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. The company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The firm’s quarterly revenue was up 95.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.87) EPS. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -3.71 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on VRDN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Monday, April 20th. Stifel Nicolaus set a $39.00 price objective on Viridian Therapeutics in a report on Wednesday, May 13th. Evercore set a $26.00 price objective on Viridian Therapeutics in a report on Friday, May 15th. Wall Street Zen raised Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, May 5th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $36.14.

Insider Buying and Selling at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the purchase, the director directly owned 5,090,928 shares in the company, valued at $86,545,776. This trade represents a 30.05% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 2.40% of the stock is currently owned by company insiders.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.